{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T11:29:50Z","timestamp":1793705390637,"version":"4.5.1"},"reference-count":200,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The association between cancer and autoimmunity is well-recognized, as represented by the increased incidence of cancer among patients with systemic autoimmune diseases; however, the underlying mechanisms remain only partially understood. On the one hand, malignancy may trigger a breakdown of immune tolerance in predisposed individuals, as autoimmune syndromes often emerge shortly after cancer diagnosis, suggesting that tumor antigens might initiate an autoimmune response. However, by involving persistent responses and the creation of a pro-inflammatory environment, the chronic immune activation characteristic of autoimmunity may promote oncogenesis. This scenario is further complicated by the use of immunosuppressive therapies for autoimmune conditions, which, as seen in transplant immunology, are associated with a higher risk of cancer, although data in rheumatology have not yielded definitive conclusions. Connective tissue diseases include systemic lupus erythematosus, primary Sj\u00f6gren syndrome, idiopathic inflammatory myopathies, systemic sclerosis, mixed connective tissue disease, and undifferentiated forms. These conditions have been variably associated with an increased risk of cancer, both at the time of disease onset and in patients with long-standing autoimmune conditions, providing a paradigm for investigating this complex interplay. Despite recent progress, many unmet needs remain that warrant further research.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1571700","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T05:34:21Z","timestamp":1746768861000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Cancer in connective tissue disease"],"prefix":"10.3389","volume":"16","author":[{"given":"Antonio","family":"Tonutti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Ceribelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Gremese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Colafrancesco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"De Santis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Selmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"102882","DOI":"10.1016\/j.autrev.2021.102882","article-title":"Autoimmunity and cancer","volume":"20","author":"Masetti","year":"2021","journal-title":"Autoimmun Rev"},{"key":"B2","first-page":"S99","article-title":"Treatment of mixed cryoglobulinemia: a rheumatology perspective","volume":"29","author":"De Vita","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"B3","article-title":"The association of Malignancy with rheumatic and connective tissue diseases","volume":"24","author":"Carsons","year":"1997","journal-title":"Semin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer","volume":"420","author":"Coussens","year":"2002","journal-title":"Nature"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe058018","article-title":"Immunosuppressive drugs and the risk of cancer after organ transplantation","volume":"352","author":"Dantal","year":"2005","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/bmjonc-2023-000037","article-title":"Use of immunosuppression and subsequent cancer incidence: cohort study","volume":"2","author":"Buchanich","year":"2023","journal-title":"BMJ Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2007.11.001","article-title":"Connective tissue diseases","volume":"21","author":"Furst","year":"2007","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00398-2","article-title":"Systemic lupus erythematosus","volume":"403","author":"Hoi","year":"2024","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1702514","article-title":"Primary Sj\u00f6gren\u2019s syndrome","volume":"378","author":"Mariette","year":"2018","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","article-title":"Idiopathic inflammatory myopathies","volume":"7","author":"Lundberg","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01692-0","article-title":"Systemic sclerosis","volume":"401","author":"Volkmann","year":"2023","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","first-page":"152678","DOI":"10.1016\/j.semarthrit.2025.152678","article-title":"Is mixed connective tissue disease (MCTD) a subtype of systemic sclerosis","author":"Tanaka","year":"2025","journal-title":"Semin Arthritis Rheum"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.150326","article-title":"Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway","volume":"70","author":"Higgs","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225727","article-title":"B-cell depletion in autoimmune diseases","volume":"83","author":"Schett","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1126\/science.1246886","article-title":"Association of the autoimmune disease scleroderma with an immunologic response to cancer","volume":"343","author":"Joseph","year":"2014","journal-title":"Science"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2019.1649596","article-title":"Predicting lymphoma development in patients with Sj\u00f6gren\u2019s syndrome","volume":"15","author":"De Vita","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes303","article-title":"Systemic sclerosis (scleroderma) and cancer risk: systematic review and meta-analysis of observational studies","volume":"52","author":"Bonifazi","year":"2013","journal-title":"Rheumatol (Oxford)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1196\/annals.1361.047","article-title":"Cancer-associated myositis: clinical features and prognostic signs","volume":"1051","author":"Ponyi","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"B21","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s40674-022-00197-2","article-title":"Management of cancer-associated myositis","volume":"8","author":"Selva-O\u2019Callaghan","year":"2022","journal-title":"Curr Treatm Opt Rheumatol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nrrheum.2018.56","article-title":"Autoantibodies in myositis","volume":"14","author":"McHugh","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.14046","article-title":"Risk factors for cancer-associated myositis: A large-scale multicenter cohort study","volume":"24","author":"Li","year":"2021","journal-title":"Int J Rheum Dis"},{"key":"B24","doi-asserted-by":"publisher","first-page":"101771","DOI":"10.1016\/j.berh.2022.101771","article-title":"Cancer and myositis: Who, when, and how to screen","volume":"36","author":"Kardes","year":"2022","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199202063260602","article-title":"Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study","volume":"326","author":"Sigurgeirsson","year":"1992","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/art.42311","article-title":"Subsets of idiopathic inflammatory myositis enriched for contemporaneous cancer relative to the general population","volume":"75","author":"Mecoli","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/art.v65.11","article-title":"Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1\u03b3","volume":"65","author":"Fiorentino","year":"2013","journal-title":"Arthritis Rheumatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-017-8652-1","article-title":"Cutaneous manifestations of dermatomyositis: a comprehensive review","volume":"53","author":"Mainetti","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1056\/NEJMicm2033425","article-title":"Dermatomyositis","volume":"384","author":"O\u2019Connell","year":"2021","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead481","article-title":"Comparison of clinical features between patients with anti-synthetase syndrome and dermatomyositis: Results from the MYONET registry","volume":"63","author":"Hum","year":"2024","journal-title":"Rheumatol (Oxford)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac144","article-title":"Cancer and immune-mediated necrotizing myopathy: a longitudinal referral case-controlled outcomes evaluation","volume":"62","author":"Shelly","year":"2022","journal-title":"Rheumatol (Oxford)"},{"key":"B32","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1001\/archderm.139.4.539-a","article-title":"A helpful clinical sign predictive of cancer in adult dermatomyositis: cutaneous necrosis","volume":"139","author":"Mah\u00e9","year":"2003","journal-title":"Arch Dermatol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.3390\/jcm9072150","article-title":"The impact of dysphagia in myositis: A systematic review and meta-analysis","volume":"9","author":"Labeit","year":"2020","journal-title":"J Clin Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab166","article-title":"A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies","volume":"60","author":"Oldroyd","year":"2021","journal-title":"Rheumatol (Oxford)"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2020.05.006","article-title":"Risk factors and cancer screening in myositis","volume":"46","author":"Moghadam-Kia","year":"2020","journal-title":"Rheum Dis Clin North Am"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-023-01045-w","article-title":"International guideline for idiopathic inflammatory myopathy-associated cancer screening: an international myositis assessment and clinical studies group (IMACS) initiative","volume":"19","author":"Oldroyd","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0094128","article-title":"Factors predicting Malignancy in patients with polymyositis and dermatomyostis: a systematic review and meta-analysis","volume":"9","author":"Lu","year":"2014","journal-title":"PloS One"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2012.07.019","article-title":"Muscle biopsy findings predictive of Malignancy in rare infiltrative dermatomyositis","volume":"115","author":"Uchino","year":"2013","journal-title":"Clin Neurol Neurosurg"},{"key":"B39","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S0140-6736(00)03540-6","article-title":"Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study","volume":"357","author":"Hill","year":"2001","journal-title":"Lancet"},{"key":"B40","doi-asserted-by":"publisher","first-page":"R70","DOI":"10.1186\/ar2987","article-title":"Cancer risks of dermatomyositis and polymyositis: a nationwide cohort study in Taiwan","volume":"12","author":"Chen","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"B41","doi-asserted-by":"publisher","first-page":"4545","DOI":"10.1038\/s41598-021-83729-5","article-title":"Reappraisal of the incidence, various types and risk factors of Malignancies in patients with dermatomyositis and polymyositis in Taiwan","volume":"11","author":"Hsu","year":"2021","journal-title":"Sci Rep"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2019.09.014","article-title":"Malignancy and myositis, from molecular mimicry to tumor infiltrating lymphocytes","volume":"29","author":"Selva-O\u2019Callaghan","year":"2019","journal-title":"Neuromuscul Disord"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1097\/01.bor.0000245721.02512.77","article-title":"Cancer and myositis: new insights into an old association","volume":"18","author":"Levine","year":"2006","journal-title":"Curr Opin Rheumatol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez572","article-title":"Anti-TIF1-\u03b3 autoantibodies: warning lights of a tumour autoantigen","volume":"59","author":"De Vooght","year":"2020","journal-title":"Rheumatol (Oxford)"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/art.33379","article-title":"Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis","volume":"64","author":"Trallero-Aragu\u00e1s","year":"2012","journal-title":"Arthritis Rheumatol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/art.40895","article-title":"The IgG2 isotype of anti-transcription intermediary factor 1\u03b3 Autoantibodies is a biomarker of cancer and mortality in adult dermatomyositis","volume":"71","author":"Aussy","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac577","article-title":"Anti-transcription intermediary factor 1-gamma IgG2 isotype is associated with cancer in adult dermatomyositis: an ENMC multinational study","volume":"62","author":"Cordel","year":"2023","journal-title":"Rheumatol (Oxford)"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex413","article-title":"Tumour TIF1 mutations and loss of heterozygosity related to cancer-associated myositis","volume":"57","author":"Pinal-Fernandez","year":"2018","journal-title":"Rheumatol (Oxford)"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/art.38863","article-title":"Expression of the dermatomyositis autoantigen transcription intermediary factor 1\u03b3 in regenerating muscle","volume":"67","author":"Mohassel","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1111\/ced.2017.42.issue-6","article-title":"Expression of the autoantigen TRIM33\/TIF1\u03b3 in skin and muscle of patients with dermatomyositis is upregulated, together with markers of cellular stress","volume":"42","author":"Scholtissek","year":"2017","journal-title":"Clin Exp Dermatol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/art.42474","article-title":"Association of anti-CCAR1 autoantibodies with decreased cancer risk relative to the general population in patients with anti-transcriptional intermediary factor 1\u03b3-positive dermatomyositis","volume":"75","author":"Fiorentino","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222441","article-title":"Coexisting autoantibodies against transcription factor Sp4 are associated with decreased cancer risk in patients with dermatomyositis with anti-TIF1\u03b3 autoantibodies","volume":"82","author":"Hosono","year":"2023","journal-title":"Ann Rheumatic Dis"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1172\/JCI150201","article-title":"Immune responses to CCAR1 and other dermatomyositis autoantigens are associated with attenuated cancer emergence","volume":"132","author":"Fiorentino","year":"2022","journal-title":"J Clin Invest"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.e06-08-0747","article-title":"Dynamic regulation of p53 subnuclear localization and senescence by MORC3","volume":"18","author":"Takahashi","year":"2007","journal-title":"Mol Biol Cell"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2024.1410130","article-title":"Genome-wide analysis reveals the MORC3-mediated repression of PD-L1 expression in head and neck cancer","volume":"12","author":"Fu","year":"2024","journal-title":"Front Cell Dev Biol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200697","article-title":"Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with Malignancy","volume":"71","author":"Ichimura","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"B57","doi-asserted-by":"publisher","first-page":"R97","DOI":"10.1186\/ar3822","article-title":"Anti-MJ\/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis\/dermatomyositis","volume":"14","author":"Ceribelli","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab518","article-title":"Anti-nuclear matrix protein 2 antibody-positive inflammatory myopathies represent extensive myositis without dermatomyositis-specific rash","volume":"61","author":"Ichimura","year":"2022","journal-title":"Rheumatol (Oxford)"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-021-08920-y","article-title":"An Italian multicenter study on anti-NXP2 antibodies: clinical and serological associations","volume":"63","author":"Fredi","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2018.11.008","article-title":"Association of anti-nuclear matrix protein 2 antibody with complications in patients with idiopathic inflammatory myopathies: A meta-analysis of 20 cohorts","volume":"198","author":"Zhong","year":"2019","journal-title":"Clin Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1068402","article-title":"Interstitial lung disease associated with inflammatory myositis: Autoantibodies, clinical phenotypes, and progressive fibrosis","volume":"10","author":"Ceribelli","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead154","article-title":"Anti-SAE autoantibody in dermatomyositis: original comparative study and review of the literature","volume":"62","author":"Demortier","year":"2023","journal-title":"Rheumatol (Oxford)"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae232","article-title":"Longitudinal study of patients with anti-SAE antibody positive dermatomyositis: a multicenter cohort study in China","volume":"64","author":"Zhang","year":"2025","journal-title":"Rheumatol (Oxford)"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2022.03.023","article-title":"Cancer associated autoantibodies in idiopathic inflammatory myopathies: A retrospective cohort from a single center in China","volume":"160","author":"Zhao","year":"2023","journal-title":"Med Clin (Barc)"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11247","article-title":"A North American cohort of anti-SAE dermatomyositis: clinical phenotype, testing, and review of cases","volume":"3","author":"Albayda","year":"2021","journal-title":"ACR Open Rheumatol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-025-01155-4","article-title":"Immune regulation by the SUMO family","author":"Tharuka","year":"2025","journal-title":"Nat Rev Immunol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12967-024-04913-5","article-title":"ROS-mediated up-regulation of SAE1 by Helicobacter pylori promotes human gastric tumor genesis and progression","volume":"22","author":"Shi","year":"2024","journal-title":"J Transl Med"},{"key":"B68","doi-asserted-by":"publisher","first-page":"2981722","DOI":"10.1155\/2024\/2981722","article-title":"Upregulated SAE1 drives tumorigenesis and is associated with poor clinical outcomes in breast cancer","volume":"2024","author":"Liu","year":"2024","journal-title":"Breast J"},{"key":"B69","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3390\/cells10010178","article-title":"SUMO-activating enzyme subunit 1 (SAE1) is a promising diagnostic cancer metabolism biomarker of hepatocellular carcinoma","volume":"10","author":"Ong","year":"2021","journal-title":"Cells"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aww054","article-title":"High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody","volume":"139","author":"Allenbach","year":"2016","journal-title":"Brain"},{"key":"B71","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41584-020-00515-9","article-title":"Immune-mediated necrotizing myopathy: clinical features and pathogenesis","volume":"16","author":"Allenbach","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.50.3.764","article-title":"Paraneoplastic necrotizing myopathy: clinical and pathological features","volume":"50","author":"Levin","year":"1998","journal-title":"Neurology"},{"key":"B73","article-title":"Paraneoplastic necrotizing myopathy presenting as severe muscle weakness in a patient with small-cell lung cancer: successful response to chemoradiation therapy","volume":"9","author":"Vu","year":"2011","journal-title":"Clin Adv Hematol Oncol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2010.05.020","article-title":"Anti-Ku antibodies: Clinical, genetic and diagnostic insights","volume":"9","author":"Belizna","year":"2010","journal-title":"Autoimmun Rev"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac003","article-title":"Autoantibodies against four-and-a-half-LIM domain 1 (FHL1) in inflammatory myopathies: results from an Australian single-centre cohort","volume":"61","author":"Galindo-Feria","year":"2022","journal-title":"Rheumatol (Oxford)"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220004","article-title":"Anti-RuvBL1\/2 autoantibodies in patients with systemic sclerosis or idiopathic inflammatory myopathy and a nuclear speckled pattern","volume":"81","author":"Vulsteke","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2019.3684","article-title":"A case of anti-RuvBL1\/2 antibody-positive systemic sclerosis overlapping with myositis","volume":"30","author":"Nomura","year":"2020","journal-title":"Eur J Dermatol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/antib12010013","article-title":"Anti-RuvBL1\/2 autoantibodies detection in a patient with overlap systemic sclerosis and polymyositis","volume":"12","author":"Di Pietro","year":"2023","journal-title":"Antibodies (Basel)"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000223","article-title":"An autoimmune myositis-overlap syndrome associated with autoantibodies to nuclear pore complexes: description and long-term follow-up of the anti-Nup syndrome","volume":"93","author":"Sen\u00e9cal","year":"2014","journal-title":"Med (Baltimore)"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1002\/art.30349","article-title":"Autoantibodies to survival of motor neuron complex in patients with polymyositis: immunoprecipitation of D, E, F, and G proteins without other components of small nuclear ribonucleoproteins","volume":"63","author":"Satoh","year":"2011","journal-title":"Arthritis Rheumatol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003431","article-title":"Anti-SMN autoantibodies in mixed connective tissue disease are associated with a severe systemic sclerosis phenotype","volume":"9","author":"El Kamouni","year":"2023","journal-title":"RMD Open"},{"key":"B82","doi-asserted-by":"publisher","first-page":"152619","DOI":"10.1016\/j.semarthrit.2024.152619","article-title":"Established and novel insights to guide cancer assessment in patients with idiopathic inflammatory myopathies","volume":"71","author":"Ceribelli","year":"2025","journal-title":"Semin Arthritis Rheumatism"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae504","article-title":"Validation of the International Myositis Assessment and Clinical Studies Group guideline on cancer risk stratification","volume":"64","author":"Tang","year":"2025","journal-title":"Rheumatol (Oxford)"},{"key":"B84","doi-asserted-by":"publisher","first-page":"103084","DOI":"10.1016\/j.autrev.2022.103084","article-title":"Primary Sj\u00f6gren\u2019s syndrome is associated with increased risk of Malignancies besides lymphoma: A systematic review and meta-analysis","volume":"21","author":"Zhong","year":"2022","journal-title":"Autoimmun Rev"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez052","article-title":"Lymphomas complicating primary Sj\u00f6gren\u2019s syndrome: from autoimmunity to lymphoma","volume":"60","author":"Nocturne","year":"2021","journal-title":"Rheumatol (Oxford)"},{"key":"B86","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3390\/medsci9010005","article-title":"Epidemiology of non-Hodgkin\u2019s lymphoma","volume":"9","author":"Thandra","year":"2021","journal-title":"Med Sci (Basel)"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(24)00183-8","article-title":"Identification and evolution of predictors of Sj\u00f6gren\u2019s disease-associated mucosa-associated lymphoid tissue lymphoma development over time: a case-control study","volume":"6","author":"Goules","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jaut.2013.10.002","article-title":"Biomarkers of lymphoma in Sj\u00f6gren\u2019s syndrome and evaluation of the lymphoma risk in prelymphomatous conditions: results of a multicenter study","volume":"51","author":"Quartuccio","year":"2014","journal-title":"J Autoimmun"},{"key":"B89","doi-asserted-by":"publisher","first-page":"102648","DOI":"10.1016\/j.jaut.2021.102648","article-title":"A biomarker for lymphoma development in Sjogren\u2019s syndrome: Salivary gland focus score","volume":"121","author":"Chatzis","year":"2021","journal-title":"J Autoimmun"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216287","article-title":"Increased risk of multiple myeloma in primary Sj\u00f6gren\u2019s syndrome is limited to individuals with Ro\/SSA and La\/SSB autoantibodies","volume":"79","author":"Mofors","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200402","article-title":"Incidence of cancer in a nationwide population cohort of 7852 patients with primary Sjogren\u2019s syndrome in Taiwan","volume":"71","author":"Weng","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"B92","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13045-017-0464-5","article-title":"Characterization and risk estimate of cancer in patients with primary Sj\u00f6gren syndrome","volume":"10","author":"Brito-Zer\u00f3n","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.937871","article-title":"Cancer risk in Hashimoto\u2019s thyroiditis: a systematic review and meta-analysis","volume":"13","author":"Hu","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/eh36vs","article-title":"Clinical and histological features of patients with primary Sj\u00f6gren\u2019s syndrome and autoimmune thyroiditis: a national multicentre cross-sectional study","volume":"41","author":"ColaFrancesco","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2016.217","article-title":"Ectopic lymphoid neogenesis in rheumatic autoimmune diseases","volume":"13","author":"Bombardieri","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1172\/JCI3234","article-title":"Antigen-driven clonal proliferation of B cells within the target tissue of an autoimmune disease. The salivary glands of patients with Sj\u00f6gren\u2019s syndrome","volume":"102","author":"Stott","year":"1998","journal-title":"J Clin Invest"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00430","article-title":"Ectopic lymphoid structures: powerhouse of autoimmunity","volume":"7","author":"Corsiero","year":"2016","journal-title":"Front Immunol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.144782","article-title":"Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of Malignant lymphoma in primary Sj\u00f6gren\u2019s syndrome","volume":"70","author":"Theander","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1002\/art.40528","article-title":"Ectopic germinal center-like structures in minor salivary gland biopsy tissue predict lymphoma occurrence in patients with primary Sj\u00f6gren\u2019s syndrome","volume":"70","author":"S\u00e8ne","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211290","article-title":"Germinal centres in diagnostic labial gland biopsies of patients with primary Sj\u00f6gren\u2019s syndrome are not predictive for parotid MALT lymphoma development","volume":"76","author":"Haacke","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1002\/art.2019.71.issue-1","article-title":"Germinal Centers in Diagnostic Biopsies of Patients With Primary Sj\u00f6gren\u2019s Syndrome Are Not a Risk Factor for Non-Hodgkin\u2019s Lymphoma but a Reflection of High Disease Activity: Comment on the Article by S\u00e8ne et\u00a0al","volume":"71","author":"Haacke","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez255","article-title":"CXCL13 as biomarker for histological involvement in Sj\u00f6gren\u2019s syndrome","volume":"59","author":"ColaFrancesco","year":"2020","journal-title":"Rheumatol (Oxford)"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.7.5130","article-title":"CXCL13, CCL21, and CXCL12 expression in salivary glands of patients with Sjogren\u2019s syndrome and MALT lymphoma: association with reactive and Malignant areas of lymphoid organization","volume":"180","author":"Barone","year":"2008","journal-title":"J Immunol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2023.01.023","article-title":"Diagnostic role of CXCL13 biomarker in primary Sjogren\u2019s syndrome patients with parotid non-Hodgkin\u2019s lymphoma complication","volume":"160","author":"Badarinza","year":"2023","journal-title":"Med Clin (Barc)"},{"key":"B105","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1080\/03009742.2024.2370109","article-title":"Lymphoma in Sj\u00f6gren\u2019s syndrome: no need for repetitive screening ultrasounds of the major salivary glands and neck in asymptomatic patients","volume":"54","author":"H\u00fcper","year":"2025","journal-title":"Scand J Rheumatol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/98vjav","article-title":"Ultrasonographic scores and parotid histopathology in Sj\u00f6gren\u2019s disease: challenges in lymphoma identification","volume":"42","author":"Giovannini","year":"2024","journal-title":"Clin Exp Rheumatol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780360405","article-title":"Cancer in systemic sclerosis","volume":"36","author":"Abu-Shakra","year":"1993","journal-title":"Arthritis Rheumatol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19950901)76:5<910::AID-CNCR2820760528>3.0.CO;2-T","article-title":"Incidence of cancer among patients with systemic sclerosis","volume":"76","author":"Rosenthal","year":"1995","journal-title":"Cancer"},{"key":"B109","article-title":"A cohort study of cancer incidence in systemic sclerosis","volume":"33","author":"Derk","year":"2006","journal-title":"J Rheumatol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1588084","article-title":"Autoantibody status in systemic sclerosis patients defines both cancer risk and survival with ANA negativity in cases with concomitant cancer having a worse survival","volume":"8","author":"Watad","year":"2019","journal-title":"Oncoimmunology"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1002\/acr.v72.11","article-title":"Incidence, risk factors, and outcomes of cancer in systemic sclerosis","volume":"72","author":"Morrisroe","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1002\/art.37969","article-title":"Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies","volume":"65","author":"Onishi","year":"2013","journal-title":"Arthritis Rheumatol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.114264","article-title":"Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database","volume":"69","author":"Tyndall","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.066068","article-title":"Changes in causes of death in systemic sclerosis, 1972-2002","volume":"66","author":"Steen","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1080\/03009742.2024.2335781","article-title":"Causes and predictors of death among Finnish patients with systemic sclerosis","volume":"53","author":"Kortelainen","year":"2024","journal-title":"Scand J Rheumatol"},{"key":"B116","doi-asserted-by":"publisher","first-page":"102507","DOI":"10.1016\/j.autrev.2020.102507","article-title":"Spanish scleroderma risk score (RESCLESCORE) to predict 15-year all-cause mortality in scleroderma patients at the time of diagnosis based on the RESCLE cohort: Derivation and internal validation","volume":"19","author":"Rubio-Rivas","year":"2020","journal-title":"Autoimmun Rev"},{"key":"B117","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1136\/ard.2006.066340","article-title":"Survival and causes of death in 366 Hungarian patients with systemic sclerosis","volume":"67","author":"Czirj\u00e1k","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2013.04.014","article-title":"The risk of cancer development in systemic sclerosis: a meta-analysis","volume":"37","author":"Zhang","year":"2013","journal-title":"Cancer Epidemiol"},{"key":"B119","doi-asserted-by":"publisher","first-page":"105618","DOI":"10.1016\/j.jbspin.2023.105618","article-title":"Identifying the risk of cancer-associated systemic sclerosis","volume":"90","author":"Guillen-Del-Castillo","year":"2023","journal-title":"Joint Bone Spine"},{"key":"B120","doi-asserted-by":"publisher","first-page":"103167","DOI":"10.1016\/j.autrev.2022.103167","article-title":"Standardized incidence ratios and risk factors for cancer in patients with systemic sclerosis: Data from the Spanish Scleroderma Registry (RESCLE)","volume":"21","author":"Carbonell","year":"2022","journal-title":"Autoimmun Rev"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev358","article-title":"Increased risk of papillary thyroid cancer in systemic sclerosis associated with autoimmune thyroiditis","volume":"55","author":"Antonelli","year":"2016","journal-title":"Rheumatol (Oxford)"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1177\/2397198318766825","article-title":"Interstitial lung disease is associated with an increased risk of lung cancer in systemic sclerosis: Longitudinal data from the Canadian Scleroderma Research Group","volume":"3","author":"Sakr","year":"2018","journal-title":"J Scleroderma Relat Disord"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2012.06.003","article-title":"Lung cancer in scleroderma: results from an Italian rheumatologic center and review of the literature","volume":"12","author":"Colaci","year":"2013","journal-title":"Autoimmun Rev"},{"key":"B124","doi-asserted-by":"publisher","first-page":"105555","DOI":"10.1016\/j.jbspin.2023.105555","article-title":"Clinical and immunological features of patients with cancer-associated systemic sclerosis: An observational study","volume":"90","author":"Lopez","year":"2023","journal-title":"Joint Bone Spine"},{"key":"B125","doi-asserted-by":"publisher","first-page":"853","DOI":"10.3390\/jcm9030853","article-title":"Biphasic temporal relationship between cancers and systemic sclerosis: A clinical series from Montpellier university hospital and review of the literature","volume":"9","author":"Partouche","year":"2020","journal-title":"J Clin Med"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e32834a5081","article-title":"Cancer and systemic sclerosis: novel insights into pathogenesis and clinical implications","volume":"23","author":"Shah","year":"2011","journal-title":"Curr Opin Rheumatol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-022-08944-y","article-title":"Autoantibodies and cancer association: the case of systemic sclerosis and dermatomyositis","volume":"63","author":"Fiorentino","year":"2022","journal-title":"Clinic Rev Allerg Immunol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2023.01.011","article-title":"Preventative care in scleroderma: what is the best approach to bone health and cancer screening","volume":"49","author":"Calderon","year":"2023","journal-title":"Rheum Dis Clin North Am"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000222","article-title":"Cancer and scleroderma: a paraneoplastic disease with implications for Malignancy screening","volume":"27","author":"Shah","year":"2015","journal-title":"Curr Opin Rheumatol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1002\/art.42663","article-title":"Distinct scleroderma autoantibody profiles stratify patients for cancer risk at scleroderma onset and during the disease course","volume":"76","author":"Kim","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-212999","article-title":"Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer","volume":"77","author":"Igusa","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.101144","article-title":"Malignancies in Italian patients with systemic sclerosis positive for anti-RNA polymerase III antibodies","volume":"38","author":"Airo\u2019","year":"2011","journal-title":"J Rheumatol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.160817","article-title":"Malignancies in patients with anti-RNA polymerase III antibodies and systemic sclerosis: analysis of the EULAR scleroderma trials and research cohort and possible recommendations for screening","volume":"44","author":"Lazzaroni","year":"2017","journal-title":"J Rheumatol"},{"key":"B134","article-title":"Clinical features of systemic sclerosis patients with anti-RNA polymerase III antibody in a single centre in Spain","author":"Callejas-Moraga","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"B135","doi-asserted-by":"publisher","first-page":"R211","DOI":"10.1186\/ar3544","article-title":"Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort","volume":"13","author":"Nikpour","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"B136","doi-asserted-by":"publisher","first-page":"R53","DOI":"10.1186\/ar4486","article-title":"Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma","volume":"16","author":"Moinzadeh","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1002\/art.42701","article-title":"Serum autoantibodies and the risk of cancer in systemic sclerosis over time","volume":"76","author":"De Santis","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-004492","article-title":"Autoantibodies, cutaneous subset and immunosuppressants contribute to the cancer risk in systemic sclerosis","volume":"10","author":"Tonutti","year":"2024","journal-title":"RMD Open"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes315","article-title":"Systemic sclerosis without antinuclear antibodies or Raynaud\u2019s phenomenon: a multicentre study in the prospective EULAR Scleroderma Trials and Research (EUSTAR) database","volume":"52","author":"Schneeberger","year":"2013","journal-title":"Rheumatol (Oxford)"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1002\/art.41493","article-title":"Cancer in systemic sclerosis: analysis of antibodies against components of the Th\/To complex","volume":"73","author":"Mecoli","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1080\/08916934.2017.1357699","article-title":"Disease-related autoantibody profile in patients with systemic sclerosis","volume":"50","author":"Liaskos","year":"2017","journal-title":"Autoimmunity"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2017.03.012","article-title":"Novel risk factors related to cancer in scleroderma","volume":"16","author":"Bernal-Bello","year":"2017","journal-title":"Autoimmun Rev"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1002\/art.40065","article-title":"Brief report: anti-RNPC-3 antibodies as a marker of cancer-associated scleroderma","volume":"69","author":"Shah","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab279","article-title":"Anti-RNPC-3 antibody predicts poor prognosis in patients with interstitial lung disease associated to systemic sclerosis","volume":"61","author":"Callejas-Moraga","year":"2021","journal-title":"Rheumatol (Oxford)"},{"key":"B145","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.3390\/jpm12122007","article-title":"Molecular pathways of breast cancer in systemic sclerosis: exploratory immunohistochemical analysis from the Sclero-breast study","volume":"12","author":"Isca","year":"2022","journal-title":"J Pers Med"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab735","article-title":"Association between autoantibodies in systemic sclerosis and cancer in a national registry","volume":"61","author":"Hoa","year":"2022","journal-title":"Rheumatol (Oxford)"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac614","article-title":"Association between anti-SSSCA1 antibodies and cancer in systemic sclerosis","volume":"62","author":"Wallwork","year":"2023","journal-title":"Rheumatol (Oxford)"},{"key":"B148","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/annrheumdis-2024-eular.1670","article-title":"OP0013 anti-Ro\/Ssa antibodies are predictive of A more severe lung involvement in patients with systemic sclerosis: A study from the Eustar Hdatabase","volume":"83","author":"Burja","year":"2024","journal-title":"Ann Rheumatic Diseases"},{"key":"B149","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13075-024-03325-6","article-title":"Clinical features of patients with systemic sclerosis positive for anti-SS-A antibody: a cohort study of 156 patients","volume":"26","author":"Watanabe","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev204","article-title":"Tumour-associated antigens in systemic sclerosis patients with interstitial lung disease: association with lung involvement and cancer risk","volume":"54","author":"De Luca","year":"2015","journal-title":"Rheumatol (Oxford)"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1007\/164_2021_554","article-title":"Malignancy: an adverse effect of immunosuppression","volume":"272","author":"Munagala","year":"2022","journal-title":"Handb Exp Pharmacol"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/87.7.524","article-title":"Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin\u2019s lymphoma","volume":"87","author":"Travis","year":"1995","journal-title":"J Natl Cancer Inst"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2021.05.017","article-title":"Cyclophosphamide-associated bladder cancers and considerations for survivorship care: A systematic review","volume":"39","author":"Chou","year":"2021","journal-title":"Urol Oncol"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"key":"B155","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s12016-023-08963-3","article-title":"Perspectives on mycophenolate mofetil in the management of autoimmunity","volume":"65","author":"Bhat","year":"2023","journal-title":"Clin Rev Allergy Immunol"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000186382.81130.ba","article-title":"Malignancy after transplantation","volume":"80","author":"Buell","year":"2005","journal-title":"Transplantation"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14979","article-title":"Mycophenolic acid and cancer risk in solid organ transplant recipients: Systematic review and meta-analysis","volume":"88","author":"Hirunsatitpron","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2021.4108","article-title":"The association between immunosuppression and skin cancer in solid organ transplant recipients: a control-matched cohort study of 2,852 patients","volume":"31","author":"Gibson","year":"2021","journal-title":"Eur J Dermatol"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2021.12.636","article-title":"Malignancy risk associated with mycophenolate mofetil or azathioprine in patients with fibrotic interstitial lung disease","volume":"161","author":"Lok","year":"2022","journal-title":"Chest"},{"key":"B160","doi-asserted-by":"publisher","first-page":"801","DOI":"10.3390\/vaccines10050801","article-title":"Dose-dependent impairment of the immune response to the moderna-1273 mRNA vaccine by mycophenolate mofetil in patients with rheumatic and autoimmune liver diseases","volume":"10","author":"De Santis","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-021-05698-4","article-title":"Efficacy and safety of rituximab therapy in patients with systemic sclerosis disease (SSc): systematic review and meta-analysis","volume":"40","author":"Moradzadeh","year":"2021","journal-title":"Clin Rheumatol"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1177\/09612033241257134","article-title":"Mortality in patients with systemic lupus erythematosus: A meta-analysis of overall and cause-specific effects","volume":"33","author":"Lee","year":"2024","journal-title":"Lupus"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2021.09.009","article-title":"Risk of Malignancy in patients with systemic lupus erythematosus: Systematic review and meta-analysis","volume":"51","author":"Clarke","year":"2021","journal-title":"Semin Arthritis Rheumatol"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1177\/09612033221122163","article-title":"Factors mediating cancer risk in systemic lupus erythematosus","volume":"31","author":"Hardenbergh","year":"2022","journal-title":"Lupus"},{"key":"B165","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s12672-024-01218-3","article-title":"Association between systemic lupus erythematosus and common female reproductive system Malignancies","volume":"15","author":"Sirong","year":"2024","journal-title":"Discovery Oncol"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170652","article-title":"Smoking is the most significant modifiable lung cancer risk factor in systemic lupus erythematosus","volume":"45","author":"Bernatsky","year":"2018","journal-title":"J Rheumatol"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac316","article-title":"Cancer occurrence after SLE: effects of medication-related factors, disease-related factors and survival from an observational study","volume":"62","author":"Zhao","year":"2023","journal-title":"Rheumatol (Oxford)"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202099","article-title":"Lymphoma risk in systemic lupus: effects of disease activity versus treatment","volume":"73","author":"Bernatsky","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"B169","doi-asserted-by":"publisher","first-page":"370516","DOI":"10.1155\/2012\/370516","article-title":"Epstein-Barr virus and systemic lupus erythematosus","volume":"2012","author":"Draborg","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1177\/0961203309102556","article-title":"Lupus and cancer","volume":"18","author":"Gayed","year":"2009","journal-title":"Lupus"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0123291","article-title":"Patients with systemic lupus erythematosus have higher prevalence of thyroid autoantibodies: a systematic review and meta-analysis","volume":"10","author":"Pan","year":"2015","journal-title":"PloS One"},{"key":"B172","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s42358-024-00353-3","article-title":"Childhood-onset systemic lupus erythematosus (cSLE) and Malignancy: a nationwide multicentre series review","volume":"64","author":"Brufatto","year":"2024","journal-title":"Adv Rheumatol"},{"key":"B173","doi-asserted-by":"publisher","first-page":"6310","DOI":"10.1038\/s41598-023-33585-2","article-title":"Bioinformatics analysis of the pathogenic link between Epstein-Barr virus infection, systemic lupus erythematosus and diffuse large B cell lymphoma","volume":"13","author":"Zhu","year":"2023","journal-title":"Sci Rep"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090644","article-title":"Natural history of cervical papilloma virus infection in systemic lupus erythematosus - a prospective cohort study","volume":"37","author":"Tam","year":"2010","journal-title":"J Rheumatol"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.34.8540","article-title":"Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes","volume":"29","author":"Kristinsson","year":"2011","journal-title":"J Clin Oncol"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2020.05.005","article-title":"Cancer and systemic lupus erythematosus","volume":"46","author":"Ladouceur","year":"2020","journal-title":"Rheum Dis Clin North Am"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez011","article-title":"Bidirectional relationship between systemic lupus erythematosus and non-Hodgkin\u2019s lymphoma: a nationwide population-based study","volume":"58","author":"Wang","year":"2019","journal-title":"Rheumatol (Oxford)"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2019-000324","article-title":"Cell of origin in diffuse large B-cell lymphoma in systemic lupus erythematosus: molecular and clinical factors associated with survival","volume":"6","author":"Tessier-Cloutier","year":"2019","journal-title":"Lupus Sci Med"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2016.23","article-title":"DNA-damaging autoantibodies and cancer: the lupus butterfly theory","volume":"12","author":"Noble","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"B180","doi-asserted-by":"publisher","first-page":"157ra142","DOI":"10.1126\/scitranslmed.3004385","article-title":"Targeting cancer with a lupus autoantibody","volume":"4","author":"Hansen","year":"2012","journal-title":"Sci Transl Med"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2016-000187","article-title":"Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma","volume":"4","author":"Bernatsky","year":"2017","journal-title":"Lupus Sci Med"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0173339","article-title":"Gene-set meta-analysis of lung cancer identifies pathway related to systemic lupus erythematosus","volume":"12","author":"Rosenberger","year":"2017","journal-title":"PloS One"},{"key":"B183","doi-asserted-by":"publisher","first-page":"3139","DOI":"10.3390\/ijms19103139","article-title":"MicroRNAs in autoimmunity and hematological Malignancies","volume":"19","author":"Di Marco","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1177\/0961203315622824","article-title":"Prevalence of premature ovarian failure in patients with systemic lupus erythematosus","volume":"25","author":"Mayorga","year":"2016","journal-title":"Lupus"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051135","article-title":"Combined oral contraceptives in women with systemic lupus erythematosus","volume":"353","author":"Petri","year":"2005","journal-title":"N Engl J Med"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1191\/096120300680198926","article-title":"Profile of sex hormones in male patients with systemic lupus erythematosus","volume":"9","author":"Mok","year":"2000","journal-title":"Lupus"},{"key":"B187","doi-asserted-by":"publisher","first-page":"5958","DOI":"10.1038\/srep05958","article-title":"A nucleolytic lupus autoantibody is toxic to BRCA2-deficient cancer cells","volume":"4","author":"Noble","year":"2014","journal-title":"Sci Rep"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604906","article-title":"Breast cancer risk in elderly women with systemic autoimmune rheumatic diseases: a population-based case-control study","volume":"100","author":"Gadalla","year":"2009","journal-title":"Br J Cancer"},{"key":"B189","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1080\/1744666X.2018.1519394","article-title":"Managing cancer risk in patients with systemic lupus erythematous","volume":"14","author":"Ladouceur","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"B190","article-title":"Cancer screening in patients with systemic lupus erythematosus","volume":"33","author":"Bernatsky","year":"2006","journal-title":"J Rheumatol"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1002\/acr.v73.12","article-title":"Cervical cancer screening in women with systemic lupus erythematosus","volume":"73","author":"Bruera","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew457","article-title":"Cumulative immunosuppressant exposure is associated with diversified cancer risk among 14\u2013832 patients with systemic lupus erythematosus: a nested case-control study","volume":"56","author":"Hsu","year":"2017","journal-title":"Rheumatol (Oxford)"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1002\/acr.v73.12","article-title":"Cancer risk in a large inception systemic lupus erythematosus cohort: effects of demographic characteristics, smoking, and medications","volume":"73","author":"Bernatsky","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew459","article-title":"Cervical neoplasia in systemic lupus erythematosus: a nationwide study","volume":"56","author":"Wadstr\u00f6m","year":"2017","journal-title":"Rheumatol (Oxford)"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000436907.56425.5c","article-title":"Predictors of cancer risk in the long-term solid-organ transplant recipient","volume":"97","author":"Sherston","year":"2014","journal-title":"Transplantation"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1038\/17401","article-title":"Cyclosporine induces cancer progression by a cell-autonomous mechanism","volume":"397","author":"Hojo","year":"1999","journal-title":"Nature"},{"key":"B197","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13075-024-03285-x","article-title":"Evaluating the safety profile of calcineurin inhibitors: cancer risk in patients with systemic lupus erythematosus from the LUNA registry-a historical cohort study","volume":"26","author":"Ichinose","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2021.1981547","article-title":"Antimalarials may reduce cancer risk in patients with systemic lupus erythematosus: a systematic review and meta-analysis of prospective studies","volume":"53","author":"Li","year":"2021","journal-title":"Ann Med"},{"key":"B199","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.3390\/diagnostics14192192","article-title":"Comparison of lineblot and immunoprecipitation methods in the detection of myositis-specific and myositis-associated antibodies in patients with idiopathic inflammatory myopathies: consistency with clinical diagnoses","volume":"14","author":"Angeli","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12696","article-title":"Anti-FIRs (PUF60) auto-antibodies are detected in the sera of early-stage colon cancer patients","volume":"7","author":"Kobayashi","year":"2016","journal-title":"Oncotarget"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1571700\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T05:34:23Z","timestamp":1746768863000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1571700\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,9]]},"references-count":200,"alternative-id":["10.3389\/fimmu.2025.1571700"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1571700","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,9]]},"article-number":"1571700"}}